From £6.99 per month
ShareProphets
The one stop source for breaking news, expert analysis, and podcasts on fast-moving AIM and LSE listed shares

MINDING THE LSE’S BUSINESS

Join for as low as £6.99 per month

With ShareProphets’ membership, you receive:

• All premium articles

• Tom Winnifrith’s Bearcast

• Access to all the entire nearly 10 year archive

• ShareProphets Daily Newsletter

Post Pfizer – what is Novacyt worth? Far from zero but it’s a slam dunk sell.

By Tom Winnifrith | Tuesday 10 November 2020


Disclosure: I have no positions in any stocks mentioned, and no plans to initiate any positions within the next 72 hours. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from ShareProphets). I have no business relationship with any company whose stock is mentioned in this article.


Some of us were always of the view that our leaders were somewhat overreacting to a disease where the average casualty lived longer than UK life expectancy and where the survival rate is 99.97%. But yesterday, Pfizer announced it has a vaccine which will protect 90% of those injected which would mean that your chances of perishing from Covid will pretty soon be less than that of being mown down by a bus carrying a West Ham team that has just won the FA Cup. So where does that leave Covid testing play Novacyt (NCYT)?

Premium content is for paid subscribers only
ShareProphets is reader-supported journalism

Become a member starting at £6.99 per month for all articles, the Bearcast, and our seven year archive.


Filed under:



Subscribe to our newsletter

Daily digest of our latest stories.



Search ShareProphets

Market News

Complete Coverage

Recent Comments

That Was the Week that Was

 

Clown

Which PR genius wrote this?

 

HAT

H&T Group – now again a Buy

Time left: 11:44:39